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Mesenchymal stem cells support 
survival and Proliferation of Primary 
human acute Myeloid leukemia 
cells through heterogeneous 
Molecular Mechanisms
Annette K. Brenner1*, Ina Nepstad1 and Øystein Bruserud1,2
1 Department of Clinical Science, Section for Hematology, University of Bergen, Bergen, Norway, 2 Department of Medicine, 
Haukeland University Hospital, Bergen, Norway
Acute myeloid leukemia (AML) is a bone marrow malignancy, and various bone marrow 
stromal cells seem to support leukemogenesis, including osteoblasts and endothelial 
cells. We have investigated how normal bone marrow mesenchymal stem cells (MSCs) 
support the in vitro proliferation of primary human AML cells. Both MSCs and primary 
AML cells show constitutive release of several soluble mediators, and the mediator 
repertoires of the two cell types are partly overlapping. The two cell populations were 
cocultured on transwell plates, and MSC effects on AML cells mediated through the 
local cytokine/soluble mediator network could thus be evaluated. The presence of nor-
mal MSCs had an antiapoptotic and growth-enhancing effect on primary human AML 
cells when investigating a group of 51 unselected AML patients; this was associated 
with increased phosphorylation of mTOR and its downstream targets, and the effect 
was independent of cytogenetic or molecular-genetic abnormalities. The MSCs also 
supported the long-term proliferation of the AML cells. A subset of the patients also 
showed an altered cytokine network with supra-additive levels for several cytokines. The 
presence of cytokine-neutralizing antibodies or receptor inhibitors demonstrated that 
AML cells derived from different patients were heterogeneous with regard to effects of 
various cytokines on AML cell proliferation or regulation of apoptosis. We conclude that 
even though the effects of single cytokines derived from bone marrow MSCs on human 
AML cells differ among patients, the final cytokine-mediated effects of the MSCs during 
coculture is growth enhancement and inhibition of apoptosis.
Keywords: acute myeloid leukemia, mesenchymal stem cells, proliferation, apoptosis, cytokines, chemokines
Abbreviations: AML, acute myeloid leukemia; Ang-1, angiopoietin 1; ATM, ataxia telangiectasia, mutated; bFGF, basic fibro-
blastic growth factor; CFU, colony-forming unit; cpm, counts per minute; ELISA, enzyme-linked immunosorbent assay; EPO, 
erythropoietin; FBS, fetal bovine serum; Flt3, FMS-related tyrosine kinase 3; G-CSF, granulocyte colony stimulating factor; 
GM-CSF, granulocyte macrophage colony-stimulating factor; HGF, hepatocyte growth factor; MMP, matrix metalloproteinase; 
MSC, mesenchymal stem cell; MSCGM, mesenchymal stem cell growth medium; NPM1, nucleophosmin; PI, propidium 
iodide; TNFα, tumor necrosis factor α; VEGF, vascular endothelial growth factor.
TaBle 1 | Biological and clinical characteristics of the 51 acute myeloid 
leukemia (aMl) patients included in the study.
Patient characteristics cell morphology cell genetics
Age FAB classificationa Cytogeneticsb
Median (years) 67 M0 3 Favorable 9
Range (years) 19–87 M1 15 Intermediate 6
M2 7 Normal 23
Gender M3 3 Adverse 10
Females 22 M4 8 n.d. 3
Males 29 M5 10
n.d. 5 Flt3 mutations
Secondary AML ITD 15
MDS 6 CD34 receptor Wild type 26
CMML 4 Negative (≤20%) 14 n.d. 10
Chemotherapy 1 Positive (>20%) 32
n.d. 5 NPM1 mutations
AML relapse 4 Insertion 16
Wild type 26
n.d. 9
aNo patient was diagnosed with FAB M6 or M7.
bPatients with favorable karyotype had inv(16); t(15;17); and t(8;21). Patients with 
adverse karyotype had −5; −7; +8 and complex karyotype with at least three 
abnormalities.
n.d., not determined.
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inTrODUcTiOn
Acute myeloid leukemia (AML) is an aggressive malignancy that 
mainly affects the elderly; the disease is characterized by bone 
marrow infiltration of immature leukemic blasts (1), and it is 
highly heterogeneous with respect to leukemia cell biology as 
well as response to therapy (2). Approximately 50–60% of AML 
patients carry clonal chromosomal abnormalities that reflect the 
chemosensitivity of the disease (3). The disease is also associated 
with specific gene mutations exhibiting prognostic impact, where 
FMS-related tyrosine kinase 3 internal tandem repeats (Flt3-ITD; 
adverse prognosis) and mutations in nucleophosmin (NPM1; 
favorable prognosis) are the most prominent (4).
Mesenchymal stem or stromal cells (MSCs) are capable of 
self-renewal and differentiation into osteoblasts, chondrocytes, 
or adipocytes (5), the most immature MSCs can also trans-
differentiate into other embryonic lineages (6, 7). The cells can 
be isolated from almost any kind of connective tissue (8, 9), and 
bone marrow MSCs provide a microenvironment for growth, dif-
ferentiation, and survival of both normal (10) and leukemic (11) 
hematopoietic cells. The bone marrow MSC population seems to 
be important in leukemogenesis (12) and also to contribute to 
chemoresistance through its release of specific soluble mediators 
(13, 14).
In this study, we have therefore characterized the cytokine-
mediated crosstalk between AML cells and normal bone marrow 
MSCs. Due to the heterogeneity of the disease, we have investi-
gated a large group of unselected patients. Our studies suggest 
that MSC-derived cytokines have antiapoptotic effects and sup-
port AML cell proliferation for most patients, but the molecular 
mechanisms causing these effects differ among patients.
MaTerials anD MeThODs
aMl Patient Population and leukemic  
cell Preparation
The study was approved by the local ethics committee (Regional 
Ethics Committee III, University of Bergen) and samples col-
lected after written informed consent. AML blasts from periph-
eral blood were derived from 51 consecutive/unselected patients 
admitted to our department for AML therapy (22 females, 29 
males; median age 67 years; range 19–87 years). A majority of 
36 patients had de novo AML (Table 1), 4 patients had relapsed 
disease, and 11 patients had secondary AML.
Acute myeloid leukemia cells were isolated from peripheral 
blood of patients with levels of circulating blasts by density gradi-
ent separation (Lymphoprep; Axis-Shield, Oslo, Norway; specific 
density 1.077 g/mL). The cells were stored in liquid nitrogen until 
use (15).
reagents
The following neutralizing antibodies and receptor antagonists 
(all from R&D Systems, Abingdon, UK) were used at the follow-
ing concentrations: (i) 100 ng/mL of affinity purified polyclonal 
antibodies (goat IgG) against the vascular endothelial growth fac-
tor (VEGF), hepatocyte growth factor (HGF), basic fibroblastic 
growth factor (bFGF), and IL-6. At this concentration, the 
antibodies will block ≥50% of receptor binding to VEGF (80 ng/
mL), HGF (8 ng/mL), bFGF (0.1 ng/mL), and IL-6 (5 ng/mL), 
thus concentrations higher than the levels in our MSC cultures 
(16); (ii) 3 µM of the CCR1 antagonists BX471 (17) and BX513 
(18); (iii) 1.5 µM of the combined CCR1 and CCR3 antagonist 
UCB35625 and its stereoisomer J113863 (19, 20); and (iv) 300 µM 
of the CXCR4 antagonist AMD3100 (13). Normal goat IgG was 
used in the antibody control cultures. Cytarabine (Sigma-Aldrich, 
St. Louis, MO, USA) was tested in dose-response experiments 
using concentrations between 12.5 nM and 2 µM (21).
In Vitro expansion of Mscs
Human MSCs from three healthy donors (MSC24429, 
MSC24539, and MSC25200) were purchased from Lonza 
(Cambrex BioScience, Walkersville, MD, USA). According to 
the distributor’s information, the cells were obtained in passage 
two and showed the ability to differentiate into the mesenchymal 
lineages. All cells tested negative for mycoplasma, bacteria, and 
fungi. The MSCs were expanded in complete mesenchymal stem 
cell growth medium (MSCGM™; Lonza), which contains 10% 
fetal bovine serum (FBS) and 4  mM l-glutamine; cells were 
trypsinized and used for the experiments in passages three or 
four. Our previous studies of global gene expression profiles of 
in vitro expanded MSCs showed no evidence for differentiation 
of such expanded MSCs (16).
analysis of aMl cell Proliferation and 
Viability in Transwell cocultures with 
Mscs
Preparation of MSC-AML Cell Cocultures
Cultures were prepared in transwell plates (Costar 3401 plates; 
Costar, Cambridge, MA, USA). The MSCs (2 ×  104 cells/well) 
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were seeded in the lower chamber in complete MSCGM™ 
medium (1 mL/well). After 3 days of culture (37°C, humidified 
atmosphere, 5% CO2) the medium was exchanged and subse-
quently 1 × 106 AML cells were added in 0.5 mL medium to the 
upper chamber separated from the MSCs by a semipermeable 
membrane (0.4 µm pore size). The cells were cultured for 3 days, 
in which the MSCs did not reach confluence.
Analysis of Cell Proliferation by 3H-Thymidine 
Incorporation
After 2 days of coculture, 275 kBq of 3H-thymidine (PerkinElmer, 
Waltham, MA, USA) was added to the upper wells and the cells 
were incubated for another day. The nuclear 3H-thymidine incor-
poration was then measured by liquid scintillation counting as 
described in detail previously (16). All cultures were prepared in 
triplicates and the median counts per minute (cpm) were used 
for all calculations. A 3H-thymidine incorporation correspond-
ing to an activity of at least 1,000 cpm was defined as detectable 
proliferation (22).
Analysis of AML Cell Viability
Acute myeloid leukemia cells and MSCs were cocultured in tran-
swell plates for 3 days before the percentage of viable leukemic cells 
was determined by flow cytometry after staining with propidium 
iodide (PI) and fluorescein isothiocyanate-conjugated Annexin V 
antibodies (Tau Technologies BV, Kattendijke, the Netherlands) 
as described in detail previously (23). Briefly, after staining with 
PI/anti-Annexin V, the flow cytometric analysis could identify 
the viable Annexin−PI−, early apoptotic Annexin V+PI−, and late 
apoptotic/necrotic Annexin V+ PI+ AML cell subsets.
We also cultured primary AML cells from 10 patients in direct 
contact with MSCs in 6-well tissue culture plates; 20,000 MSCs 
were precultured for 3 days before 1 ×  106 primary AML cells 
were added to each well. AML cell viability was analyzed 20 h later 
before the MSCs reached confluence.
analysis of the cytokine Profile in Msc-
aMl cell Transwell cocultures
Supernatants were harvested from the lower chambers and 
stored at −80°C. The following cytokine levels were determined 
by Luminex analyses or enzyme-linked immunosorbent assay 
(ELISA) (R&D Systems): (i) the chemokines CCL2-5 and 
CXCL1/5/8/10/11, (ii) the interleukins IL-1β/1RA/6/10/33, (iii) 
the matrix metalloproteinases MMP-1 and -2, (iv) tumor necrosis 
factor-α (TNFα), and (v) granulocyte colony-stimulating factor 
(G-CSF), granulocyte macrophage colony-stimulating factor 
(GM-CSF), HGF, bFGF, VEGF, and soluble angiopoietin 1 (Ang-
1) receptor Tie-2.
long-term In Vitro aMl-Msc cocultures 
and analysis of colony-Forming cells
Cocultures of MSCs with primary AML cells were prepared as 
described above. The blasts were transferred weekly to new upper 
chambers of transwell cocultures where fresh MSCs had been 
seeded in the lower chambers 3 days in advance. The medium 
was exchanged twice a week throughout the 3 weeks of culture 
period in transwell cocultures. After 3 weeks, the AML cells were 
harvested and subsequently seeded in the colony-formation 
assay to estimate the number of colony-forming units (CFU). We 
used two different colony-formation assays; MethoCult™ H4434 
Classic and H4534 Classic without erythropoietin medium 
(StemCell Technologies, Vancouver, BC, Canada). The cells were 
seeded in duplicate in 24-well plates with 0.5 mL medium/well. 
Colonies containing more than 30 cells were scored using an 
inverted microscope after 14 days of in vitro culture.
analysis of intracellular signaling and 
h2aX Phosphorylation
Antibodies
The following antibodies were used for analysis of protein 
phosphorylation: Alexa Fluor® 647 Mouse anti-PDPK1 (pS241), 
Alexa Fluor® 647 Mouse anti-PKCα (pT497), Alexa Fluor® 647 
Mouse anti-Akt (pS473), phycoerythrin (PE) Mouse Anti-Akt 
(pT308), PE Mouse Anti-mTOR (pS2448), Alexa Fluor® 647 
Mouse anti-4E-BP1 (pT36/pT45), Alexa Fluor® 647 Mouse 
anti-elF4E (pS209), Alexa Fluor® 647 Mouse anti-S6 (pS244), 
PE Mouse anti-S6 (pS240), V450 Mouse anti-S6 (pS235/pS236) 
Alexa Fluor® 647 Mouse anti-PKCα (pT497) (all from BD 
Biosciences, Franklin Lakes, NJ, USA), and mTOR (7C10) Rabbit 
mAb (Alexa Fluor® 647 Conjugate) (Cell Signaling Technology, 
Danvers, MA, USA).
Preparation of Conditioned Medium
MSC24539 was cultured as described above and the conditioned 
medium harvested before the cells reached confluence.
Analysis of Protein Phosphorylation
Thawed, cryopreserved leukemic cells were incubated for 
20  min in culture medium, thereafter incubated with condi-
tioned medium (final concentration 50%) for 30  min before 
being directly fixed in 1.5% paraformaldehyde and thereafter 
permeabilized with methanol. The cells were then rehydrated 
by adding 2 mL phosphate-buffered saline (PBS), gently resus-
pended, and then centrifuged. The cell pellet was washed twice 
with 2  mL PBS and resuspended in 150  µL PBS +  0.1% BSA 
(Sigma-Aldrich). The washed cells were blocked with immu-
noglobulin (Octagam; Octapharma, Jessheim, Norway) and 1% 
BSA, and split evenly into separate tubes (1 × 105 cells/sample) 
before staining. All staining panels included the same live dead 
discriminator FITC Mouse anti-Cleaved PARP (Asp214; BD 
Biosciences) and Alexa Fluor® 647 Mouse anti-Cleaved PARP 
(Asp 214; BD Biosciences), as well as one blank sample. Flow 
cytometric analysis of protein phosphorylation was performed 
as described in detail previously (24).
Analysis of H2AX Phosphorylation
The percentage of phosphorylated compared to total H2AX was 
detected using a cell-based ELISA kit [Phospho-Histone H2AX 
(S139) Immunoassay; R&D Systems]. The assay was performed 
according to the manufacturer’s instruction for suspension cells; 
5 × 104 AML cells were incubated for 16 h in both MSC medium 
and MSC-conditioned medium (final concentration of 50%).
FigUre 1 | The effect of normal bone marrow mesenchymal stem 
cells (Mscs) on in vitro proliferation and viability of primary human 
acute myeloid leukemia (aMl) cells; a comparison of Mscs derived 
from three healthy donors (Msc24429, Msc24539, Msc25200). 
Primary human AML cells derived from 18 consecutive/unselected leukemia 
patients were cocultured with normal MSCs from the three donors. The 
MSCs were initially cultured for 3 days to allow them to establish adherent 
in vitro proliferation; primary human AML cells were then added and both 
leukemia cell proliferation and viability were assayed after additional 3 days of 
culture. [(a), upper part] Proliferation was assayed as 3H-thymidine 
incorporation. The results for each patient are presented as nuclear thymidine 
incorporation (counts per minute, cpm). The p-value for the statistical 
comparison of the overall results is given at the top of the figure for each of 
the individual MSC. Each line represents the results for one patient. [(B), 
lower part] Leukemia cell viability was assayed by the Annexin V-PI flow 
cytometric assay. The p-value for the statistical comparison of the overall 
results for each of the MSCs is given at the top of the figure for the MSCs. 
Each line represents the results for one patient.
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statistical and Bioinformatical analyses
The statistical analyses were performed with the IBM Statistical 
Package for the Social Sciences (SPSS) version 23 (Chicago, 
IL, USA). The Wilcoxon signed-rank test was used to compare 
paired samples, whereas Kruskal–Wallis and Mann–Whitney 
U-tests were used to compare different groups. The χ2 test 
was used to analyze categorized data and the Kendall’s tau-b 
test for correlation analyses. P-values <0.05 were regarded as 
statistically significant. Supervised hierarchical clustering was 
performed using the J-Express 2012 software (MolMine AS, 
Bergen, Norway). The data were log(10) transformed prior to 
clustering.
resUlTs
human Mscs increase the Proliferation of 
Primary human aMl cells during In Vitro 
coculture
Primary AML cells from 18 consecutive patients were 
cocultured with normal MSCs from the three different 
donors (MSC24429, MSC24539, and MSC25200) in transwell 
plates. AML cell proliferation was determined after 3 days of 
culture. AML cell proliferation was significantly increased 
by coculture with MSCs compared with the corresponding 
control cultures with AML cells alone (Figure  1A); this 
increase reached statistical significance for all three MSC 
donors (p ≤ 0.001, Wilcoxon’s signed-rank test), even though 
the AML cells showed undetectable proliferation for two 
patients, both when cultured in medium alone and in the 
presence of all three MSC donor cells. The other 16 patients 
showed increased proliferation for at least one of the three 
MSCs. The median increase in 3H-thymidine incorporation 
corresponded to approximately fivefold increase for each of 
the three donors.
human Mscs have antiapoptotic effect 
on In Vitro cultured Primary aMl cells
Primary AML cells show spontaneous or stress-induced apop-
tosis during in vitro culture (25). We prepared in vitro transwell 
cocultures for MSCs and AML cells derived from the same 18 
patients as tested in the proliferation assay (see above). MSCs 
were pre-cultured for 3  days before AML cells were added 
and leukemic cell viability assayed after 3 days of coculture by 
flow cytometric analysis. The effect of all three human bone 
marrow MSCs was investigated (MSC24429, MSC24539, 
and MSC25200). The results are summarized in Table S1 in 
Supplementary Material and presented in detail in Figure 1B. 
AML cell viability showed a wide variation after three days of 
in  vitro coculture (variation range 0.4–84.7% viability). When 
comparing the overall results, the fraction of viable cells was 
significantly increased (p < 0.001, Wilcoxon’s signed-rank test) 
after coculture in the presence of all three MSCs compared with 
the corresponding MSC-free controls, and the median fraction 
of viable cells was approximately doubled for each of the three 
MSC donors.
FigUre 2 | The effects of mesenchymal stem cells (Mscs) on acute myeloid leukemia (aMl) cell proliferation/viability in suspension cultures and 
aMl cells tested in a clonogenic assay. The effect of MSCs on the in vitro proliferation [(a), left] and viability [(B), middle] of primary human AML cells derived 
from 51 consecutive patients was examined. The AML cells were then cocultured with normal MSC24539. The MSCs were initially cultured for 3 days to allow them 
to establish adherent in vitro proliferation; primary human AML cells were thereafter added and (a) leukemia cell proliferation was assayed as 3H-thymidine 
incorporation after additional 3 days of culture; additionally, (B) AML cell viability was assayed by the Annexin V-PI flow cytometric assay. The p-values for the 
statistical comparison of the overall results are given at the top of the figure. Each line represents the results for one patient. [(c), right] The effects of MSCs on 
clonogenic AML cells were also investigated. The leukemic cells were cultured either in medium alone or in transwell cocultures together with MSC24593 for 
3 weeks; the number of clonogenic cells were thereafter compared for AML cells precultured in medium alone and together with MSCs. The total culture period was 
thus 5 weeks. The MSCs significantly increased the number of colony-forming units (p-values are given on top of the figure) in growth media both with and without 
erythropoietin. The results are presented as mean of duplicate samples (average deviation from mean corresponding to 1.3 colonies and 8.7% of the total colony 
number). Each line represents the results for one patient.
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The growth-enhancing and antiapoptotic 
effects of human Mscs on Primary 
human aMl cells—a study of Patient 
heterogeneity for a group of 51 
consecutive/Unselected Patients
Because the proliferation and viability results were consist-
ent among MSC donors, the comparison of MSC effects for a 
larger group of 51 consecutive patients was performed only for 
MSC24539. MSC-induced enhancement of AML cell prolif-
eration in transwell cocultures was highly significant also when 
analyzing the overall results for this larger group of patients 
(Figure 2A; p < 0.00001, Wilcoxon’s signed-rank test). The growth 
enhancement showed no significant association with AML cell 
differentiation (morphology according to FAB classification, 
CD34 expression), karyotype (favorable/intermediate/adverse/
normal), or Flt3/NPM1 mutations (data not shown). Finally, 
cells from 11 patients showed detectable proliferation neither 
in medium alone nor in cocultures with MSC24539. For five 
additional patients, the presence of MSCs showed no or minimal 
growth enhancement, corresponding to less than 20% alteration 
and an absolute change of less than 2,000 cpm in the presence of 
MSCs. These 16 patients differed significantly from the other 35 
patients with regard to cell differentiation as CD34− cells showed 
weaker proliferation in the presence of MSCs than CD34+ cells 
(8/14 CD34− patients with non-proliferating cells in contrast to 
only 6/32 CD34− patients with proliferating cells; p = 0.011, χ2 
likelihood ratio) (data not shown).
The same 51 patients were also tested in transwell cocultures 
with regard to a MSC-associated antiapoptotic effect; viability 
analyzed by the Annexin V-PI assay was then compared for AML 
cells cultured in medium alone or cocultured with MSC24539 
for 3 days. The presence of MSCs increased AML cell viability 
significantly also when testing this extended patient group 
(Figure  2B; p  <  0.00001, Wilcoxon’s signed-rank tests). This 
antiapoptotic effect showed no significant association with AML 
cell differentiation, karyotype, or Flt3/NPM1 mutations (data not 
shown). However, proliferation <1,000  cpm in the presence of 
MSCs seemed to be associated with weaker antiapoptotic effects 
of MSCs; i.e., 8/21 patients with viability increase <10% points 
and 0/20 patients with an increase >20% points showed undetect-
able proliferation in cocultures (p = 0.001, χ2 likelihood ratio).
Because primary AML cells derived from 16 patients showed 
undetectable proliferation during coculture with MSCs, we also 
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analyzed separately the effect of MSCs on AML cell viability 
for these patients. However, when analyzing the overall results, 
a highly significant increase in AML cells viability (p <  0.001) 
after MSC coculture was seen also for these 16 patients with non-
proliferating AML cells, and a >10% point increase was seen for 
eight of these patients (see above). Thus, the MSC effect on AML 
cell viability is not only caused by the increased proliferation but 
also by additional effects possibly affecting the balance between 
pro- and antiapoptotic signaling.
normal human Mscs support the long-
term Proliferation of Primary human aMl 
cells
To further investigate the MSC effects on AML cell proliferation, 
we used an in vitro model based on 21 days of coculture; this is 
the same culture period as used previously by Griessinger et al. 
(26) in their studies of leukemia-initiating AML cells. After this 
period of transwell cocultures, the number of colony-forming 
cells was compared for leukemia cells cultured alone and cells 
cocultured with normal MSCs. We investigated AML cells from 
eight patients showing both enhanced proliferation and viability 
in the short-term assays described above. All except one patient 
showed an increased number of viable cells after 21 days of cocul-
ture with the normal MSC24539 cells (data not shown). After 
the initial 21  days culture period, the cells were seeded in the 
CFU assays. Even though the culture medium was different in the 
CFU assays compared with the transwell cocultures containing 
MSC medium, colony formation could be detected for seven of 
the eight patients. For all these seven patients, we observed an 
increased number of CFUs in the AML cell populations previ-
ously cocultured with MSCs compared with the corresponding 
control cultures where AML cells were cultured alone without 
MSCs in the lower transwell chamber (Figure  2C). Thus, the 
MSC-associated growth enhancement also includes long-term 
proliferating AML cells.
normal human Mscs have antipoptotic 
effects on Primary human aMl cells also 
in the Presence of cytarabine
We investigated the effect of 50  nM cytarabine on primary 
human AML cells derived from 10 patients. All patients showed 
an increase in leukemia cell viability corresponding to >20% 
in presence of MSC24539. The cytarabine concentration was 
chosen based on dose-response (2 µM, 0.5 µM, 125 nM, 50 nM, 
and 12.5 nM) pilot experiments, which showed that cytarabine at 
50 nM decreased AML cell viability for a marked subset of patients 
when using our in  vitro models (Figure S1 in Supplementary 
Material). These results show that there is heterogeneity among 
patients with regard to the proapoptotic effect of cytarabine, and 
decreased AML cell viability was seen only for a subset of patients 
when testing cytarabine at concentrations 12.5–500 nM and with 
a large overlap between the effects of 50 and 500 nM. At the same 
time, the drug had a clear antiproliferative effect even at 50 nM 
and at higher concentrations no detectable cytokine-dependent 
proliferation could be detected (data not shown). Finally, the 
concentrations 50–500 nM correspond to levels reached in vivo 
and 50 nM is close to the steady-state concentrations seen during 
conventional AML induction treatment and higher than the lev-
els reached during low-dose subcutaneous cytarabine treatment 
(27); both these therapeutic strategies for cytarabine treatment 
can induce complete remissions (27, 28).
Primary AML cells were cultured in transwell cultures for 20 h 
either alone or in coculture with MSC24539, and cultures with/
without MSCs were prepared with and without 50 nM cytarabine 
(Figure  3A). The present independent experiments confirmed 
that patients are heterogeneous with regard to susceptibility to 
cytarabine; a reduction in the number of viable cells exceeding 
5% was seen for 5 out of 10 patients in the present experiments 
and for 16 out of 32 patients in the previous dose-response stud-
ies. Furthermore, the percent cytarabine-induced decrease of 
AML cell viability for the five patients in the present study was 
significantly higher for cells cultured in medium alone (median 
decrease 9%, range 6–23%) compared with cells in coculture with 
MSC24539 (median decrease 4%, range 12–20%; p =  0.045). 
Finally, increased AML cell viability was seen for all 10 patients 
in MSC cocultures, both in presence and absence of 50  nM 
cytarabine.
We then compared the overall effects of MSCs on AML 
cell viability, i.e., leukemic cells cultured in direct contact with 
MSCs, on the viability of primary human AML cells derived 
from the same 10 patients as used above. Cytarabine was tested 
at 50 and 500 nM, the last concentration corresponding to the 
highest steady-state levels seen during conventional doses of 
100–200 mg/m2 as daily continuous intravenous infusions (27). 
The presence of MSCs caused a comparable increase in AML 
cell viability in these direct-contact experiments as described 
above for the transwell cocultures and similar to the transwell 
cocultures 50 nM cytarabine induced reduction of cell viability 
for five patients also in these direct-contact experiments (data 
not shown). In contrast, 500 nM cytarabine caused a significant 
reduction in AML cell viability for all patients, and this reduction 
was partly counteracted by the presence of MSCs as the AML 
cell viability was significantly increased for cytarabine-containing 
cultures with MSCs compared with corresponding cultures with-
out MSCs. But the viability was still significantly lower than for 
drug-free direct cocultures (Figure 3B). Thus, the proapoptotic 
effect of cytarabine can be detected also in our in vitro model; 
this cytarabine effect can be partly counteracted by MSCs and 
taken together our overall results suggest that cytokine-mediated 
crosstalk between MSCs and AML cells can contribute to this 
effect.
effects of Mscs on h2aX Phosphorylation 
and mTOr activation in Primary human 
aMl cells
Phosphorylation of Histone H2AX can be seen as part of the 
DNA damage response and ATM activation; the phosphoryla-
tion can then be an early apoptotic event and has been used as 
an early marker of apoptosis induction (29). We performed 
cell-based ELISA prepared from cells cultured in MSC medium 
and in MSC24539-conditioned medium (50% final concentra-
tion; for the cytokine profile of this conditioned medium see 
FigUre 3 | effects of mesenchymal stem cells (Mscs) on primary human acute myeloid leukemia (aMl) cells treated with cytarabine; (a) effect of 
50 nM cytarabine-exposure on aMl cell viability in transwell cocultures and (B) effect of 500 nM cytarabine tested in direct-contact cocultures. 
Primary AML cells derived from the same 10 patients were included in all these studies, and MSC24539 was used in all experiments. The AML cell viability was 
analyzed by flow cytometry. [(a), transwell cocultures] For each patient, we compared cultures containing AML cells alone (AML) or AML cells plus MSCs 
(AML + MSC). The three figures from left to the middle right show (i) AML cell viability for cells cultured in medium alone with or without MSCs; (ii) AML cell viability in 
the presence of 50 nM cytarabine for leukemic cells cultured with and without MSCs; and (iii) a comparison of the medium culture ratio (i.e., viable cells in 
cytarabine-containing cultures versus drug-free controls; medium alone) and MSC culture ratio (i.e., viable cells in cytarabine-containing cultures versus drug-free 
controls; MSCs being added to both cultures). The results for the five patients (solid lines) for which 50 nM cytarabine exhibited a proapoptotic effect in the presence 
of MSCs are indicated. The results for one responding patient are presented in detail (right part of the figure; i/ii: drug-free control, iii/iv: 50 nM cytarabine without 
and with MSCs, respectively); the percentage of viable cells (population at the lower left) is indicated in the figures for each of the four cultures. [(B), direct-contact 
cultures] The left part of the figure compares the medium culture ratio (i.e., viable cells in cytarabine-containing cultures versus drug-free controls; medium alone) 
and MSC culture ratio (i.e., viable cells in cytarabine-containing cultures versus drug-free controls; MSCs being added to both cultures) when testing 500 nM 
cytarabine. The right part of the figure shows the percentage of viable primary AML cells (10 patients tested, one patient not tested for AML cells + cytarabine +  
MSC) cultured in medium alone, together with MSCs, in medium containing 500 nM cytarabine, and together with 500 nM cytarabine and MSCs.
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Table  2). The percentage of phosphorylated H2AX showed 
a strong inverse correlation with AML cell viability for AML 
cells cultured in medium alone (Kendall’s tau; p < 0.0002), i.e., 
H2AX phosphorylation seems to be a marker of spontaneous 
in vitro apoptosis during culture of AML cells alone. However, 
significantly increased H2AX phosphorylation was observed 
after coculture with MSC-conditioned medium compared with 
leukemic cells cultured in medium alone (Figure  4A), and for 
TaBle 2 | cytokine excretion levels for 23 meditators from 51 acute myeloid leukemia (aMl) blast supernatants (aMl cells alone), aMl blasts in 
coculture with mesenchymal stem cells (Mscs) (cocultures of aMl cells and Msc24539) and only Mscs (Msc24539).
aMl cells alone cocultures of aMl cells and Msc24539 Msc24539 
alone
p-Value 
(supra-
additive)
Mediator # Patients Median 
conc.  
(pg/ml)
range (pg/ml) # Patients Median conc. 
(pg/ml)
range (pg/ml) Mean conc. 
(pg/ml)
CXCL5 51 368 9.0–155,581 51 3,771 17–>213,550 25 <0.001
CXCL8 51 4,872 257–210,154 51 5,834 457–379,791 204 0.005
GM-CSF 50 3.5 n.d.–834 51 10 0.1–2,673 1.2 <0.001
IL-1RA 50 1,917 5.6–>25,500 50 1,562 5.6–>25,500 n.d. n.s.
CCL5 50 56 n.d.–728 50 68 n.d.–17,161 2.9 n.s.
CXCL1 49 330 n.d.–35,641 51 11,316 24–42,042 32 <0.001
MMP-1 49 71 n.d.–14,263 51 18,223 157–>37,500 221 <0.001
CCL3 49 209 n.d.–41,519 51 234 8.0–42,167 12 <0.001
CCL4 48 235 n.d.–11,634 51 223 36–62,098 120 0.043
TNFα 45 6.0 n.d.–1,487 46 7.1 n.d.–10,676 0.8 0.037
bFGF 43 8.5 n.d.–57 50 19 n.d.–368 n.d. <0.001
CCL2 51 992 9.2–22,859 51 3,888 613–20,621 2,643 n.s.
MMP-2 51 3,993 837–18,565 51 23,957 18,594–55,147 17,428 <0.001
CXCL10 39 7.1 n.d.–2,858 43 26 n.d.–2,882 n.d. 0.003
IL-6 39 14 n.d.–3,397 51 2,775 706–10,632 1,895 <0.001
CXCL11 37 4.1 n.d.–486 40 5.1 n.d.–377 1.9 0.014
IL-1β 29 3.5 n.d.–970 35 14 n.d.–21,593 n.d. <0.001
IL-10 24 n.d. n.d.–60 30 n.d. 0.8–601 n.d. <0.001
IL-33 15 n.d. n.d.–2.9 15 n.d. n.d.–14 n.d. n.s.
G-CSF 14 n.d. n.d.–559 31 8.2 n.d.–>10,500 n.d. <0.001
HGF 51 51 1.4–2,133 51 100 28–2,277 183 (0.001)
VEGF 50 17 n.d.–290 51 967 483–3,107 1,344 n.s.
Tie-2 45 50 n.d.–145 46 42 n.d.–298 14 (0.004)
n.d., below detection limit; n.s., not significant; GM-CSF, granulocyte macrophage colony-stimulating factor; bFGF, basic fibroblastic growth factor; G-CSF, granulocyte colony-
stimulating factor; HGF, hepatocyte growth factor; VEGF, vascular endothelial growth factor.
The soluble mediators are divided into three subgroups: cytokines that are released for a large majority of patients in both medium and coculture (above); mediators that are 
excreted for a subset of patients when leukemic cells were cultured in medium alone (middle); cytokines that are released to a significantly higher degree in MSCs than in AML 
cells alone or in coculture with MSCs, or with higher values in AML cells alone compared to cocultures. The background from the growth medium was subtracted from all values. 
p-Values (Wilcoxon test) for coculture values compared to additive levels of AML cells and MSCs are included on the right; significant p-values thus indicating a supra-additive effect. 
Values in brackets (HGF and Tie-2) indicate that coculture levels are significantly lower than the expected levels from secretion of AML cells and MSCs alone.
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these cultures, no significant association between viability 
and H2AX phosphorylation could be detected. This effect was 
also independent of AML cell proliferation and could be seen 
both for patients with increased proliferation in the presence 
of MSC-conditioned medium and patients with undetectable 
proliferation both with and without conditioned medium (data 
not shown). Thus, as will be discussed later, the increased H2AX 
phosphorylation in the presence of MSC-derived medium does 
not reflect increased apoptotic activity but rather a restoration 
of the decreased DNA damage response known to be present in 
primary human AML cells (30).
We also investigated the effect of MSC-conditioned medium 
on Akt-mTOR signaling in primary human AML cells. An 
increased MSC-associated phosphorylation/activation of mTOR 
and its downstream targets, S6K1 and 4E-BP1, was then observed 
(Wilcoxon’s signed-rank test; p = 0.005; Figure 4B). The other 
upstream mediators did not differ significantly. Thus, MSCs alter 
H2AX phosphorylation as well as mTOR signaling in primary 
human AML cells, and as will be discussed later these effects may 
be important both for the MSC-associated growth enhancement 
and antiapoptotic effect of primary human AML cells.
The local cytokine network is altered 
during coculture of normal Mscs and 
Primary aMl cells
We determined the supernatant levels for 23 soluble mediators 
in transwell cocultures of MSC24539 and AML cells derived 
from all 51 patients (Table 2; Tables S2 and S3 in Supplementary 
Material). Our present study of this larger group confirmed 
the previous observations from a small group of 18 patients 
(16). First, the constitutive mediator release by primary AML 
cells shows a wide variation for each individual mediator, and 
this patient heterogeneity was maintained in cocultures as we 
observed significant correlations between the levels for AML 
cells cultured alone and the corresponding coculture for 22 of 
the 23 cytokines (Kendall’s tau correlation analysis), VEGF being 
the only exception. Second, relatively high levels were detected 
for most mediators in transwell cocultures both when compared 
FigUre 4 | effects of mesenchymal stem cell (Msc)-conditioned 
medium on primary human acute myeloid leukemia (aMl) cells; a 
study of h2aX phosphorylation and mTOr signaling. (a) The change in 
percentage of phosphorylated H2AX for AML cells cultured in MSC-
conditioned medium (CM, 50%) compared to medium alone. (B) The effect 
of MSC-conditioned medium on the phosphorylation of mTOR and its 
downstream targets. For each patient, we compared the level of 
phosphorylation for AML cells cultured with MSC-conditioned medium versus 
control cells cultured in medium alone. The results are presented as the 
relative level, i.e., the levels for MSC-conditioned cultures versus control 
cultures. The value marked with an asterisk represents a value that was 
undetectable in the control; for simplicity, the ratio was set to the same value 
as the highest observed ratio in the data series.
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with AML cells and MSC24539 cells cultured alone. Only two 
exceptional cytokines (HGF and VEGF, see Table  2) showed 
lower levels in the cocultures than in cultures of MSC24539 alone, 
and Tie-2 additionally showed higher levels in AML cell cultures 
than in cocultures. Third, supra-additive levels (i.e., cytokine 
levels in coculture supernatants exceeding the summarized levels 
for MSCs and AML cells cultured alone) were seen for several 
cytokines and reached statistical significance (Wilcoxon’s signed-
rank tests, p ≤  0.005 if not stated otherwise) when comparing 
the overall results for CCL3, CCL4 (p = 0.043), CXCL1, CXCL5, 
CXCL8, CXCL10, CXCL11 (p = 0.014), IL-1β, IL-6, IL-10, TNFα 
(p = 0.037), bFGF, G-CSF, GM-CSF, MMP-1, and MMP-2. Thus, 
even though individual differences among patients are main-
tained during coculture, several mediators show increased levels 
in cocultures and supra-additive levels are common.
To further investigate the patient heterogeneity, we performed 
a cluster analysis (Figure 5). For each mediator and patient, we 
determined the ratio between the mediator level in coculture 
relative to the sum of the levels for MSC24539 and AML cells 
cultured alone. These ratios were log(10) transformed before the 
clustering; hence a value >0 indicates a supra-additive effect. The 
patients then separated into two main clusters: (i) one subgroup 
of 22 patients characterized by strong supra-additive effects for 
several cytokines, especially, CXCL1/5, IL-1β/10, TNFα, MMP-1, 
G-CSF, and GM-CSF and (ii) another patient subset with generally 
weaker effects. The patient subgroup with strong supra-additive 
effects was also (according to χ2 likelihood analyses) character-
ized by a significantly higher number of patients (17/22 versus 
12/29, p = 0.009) showing detectable proliferation when cultured 
in the FBS-containing MSC medium alone without MSCs and 
also a higher number of patients (10/22 versus 0/29, p < 0.0001) 
with high AML cell proliferation exceeding >20,000  cpm in 
the cocultures. The supra-additive subset also showed a higher 
fraction of patients with cell viability >50% after coculture with 
MSCs (16/22 versus 11/29, p =  0.012). Finally, monocytic dif-
ferentiation (FAB-M4/M5) was also more common among these 
patients (10/22 versus 5/29, p =  0.019). However, even though 
there was an association between supra-additive cytokine levels 
and high AML cell viability/proliferation in the cocultures, these 
supra-additive levels do not simply reflect increased proliferation/
viability because supra-additive levels would then be expected for 
all the mediators and not only for a subset as we observed.
The cytokines important for  
Msc-Mediated growth enhancement of 
aMl cells Differ among Patients
To further study the cytokine-mediated crosstalk between MSCs 
and AML cells, we investigated the effects of cytokine-neutralizing 
antibodies and receptor antagonists on AML cell proliferation 
and viability in transwell cocultures with MSC24539. We then 
tested inhibitors of cytokines released by MSCs and being 
able to modulate AML cell proliferation (31–35), including (i) 
antibodies against VEGF, HGF, bFGF, and IL-6; (ii) the CCR1 
antagonists BX471 (17) and BX513 (18); (iii) the combined CCR1 
and CCR3 antagonist UCB35625 and its stereoisomer J113863 
(19, 20); and (iv) the CXCR4 antagonist AMD3100 (13). The 
initial experiments included AML cells from eight patients that 
showed increased proliferation in cocultures corresponding to at 
least 3,000 cpm; this selection was made to be able to detect an 
inhibitory effect. Inhibition of AML cell proliferation for at least 
four patients was seen for anti-bFGF, anti-IL-6, the CCR1/CCR3 
inhibitor J113863, and the CCR1 antagonists BX471 and BX513, 
whereas the CXCR4 inhibitor AMD3100 inhibited MSC24539 
proliferation for four patients. These agents were further tested 
for 24 additional patients with an AML cell proliferation of at least 
2,000 cpm in coculture. All but two of these patients then showed 
MSC-induced growth enhancement. When analyzing the overall 
results, none of the antibodies/inhibitors had any statistically 
significant effect, but the following observations were made for 
single mediators:
•	 Normal karyotype. The patients were heterogeneous with 
regard to karyotype. The only subset being large enough for 
statistical analysis was the 15 patients with normal karyotype, 
and for this subset, anti-IL-6 had a significant antiproliferative 
effect (Figure  6A, Wilcoxon’s test, p =  0.027) of borderline 
significance.
•	 Patients with and without NPM1 mutations. NPM1 insertions 
were detected for 13 of the 32 patients, and all of them had 
normal karyotype. As would then be expected, anti-IL-6 
had an antiproliferative effect for NPM1-mutated patients, 
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FigUre 6 | cytokine-targeted treatment during coculture of primary human acute myeloid leukemia (aMl) cells and bone marrow mesenchymal 
stem cells (Mscs); a comparison of patients with different karyotype (a) and patients with and without NPM1 mutations. (a) Proliferative AML cell 
responses were compared for cocultures prepared with an IL-6 specific antibody and control antibody. The study included patients with normal AML cell karyotype 
(n = 15), favorable (n = 5), intermediate (n = 4), and adverse (n = 7) cytogenetics. The results for individual patients are presented as the proliferative response in 
cultures with anti-IL-6 relative to the proliferation in control cultures. The IL-6-specific antibody decreased the proliferation only for patients with normal cytogenetics 
but not for the other patients (Wilcoxon’s test for paired samples). (B) AML cell proliferation was also compared for patients with (gray columns) and without NPM1 
mutations (white columns). Decreased AML cell proliferation was seen for several cytokine-directed treatment, especially chemokine-directed interventions 
(Wilcoxon’s test for paired samples for IL-6/bFGF, χ2 likelihood analyses for the chemokines). The box-plots show the median value, the 25 and 75% quartiles and 
the variation range (minimum to maximum value).
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but the statistical comparison reached only borderline sig-
nificance (Wilcoxon’s test, p = 0.033). The same was true for 
anti-bFGF, which had an antiproliferative effect for patients 
with NPM1-wt (Figure  6B, Wilcoxon’s test, p  =  0.036). 
Because several patients showed a relatively strong effect of 
 chemokine-targeting pharmacological intervention we used 
statistical analysis based on categorized data when compar-
ing NPM1-mutated and NPM1-wt patients. A significant 
alteration of AML cell proliferation was then defined as a 
difference having an absolute value of >2,000 cpm and in 
addition being >20% of the corresponding control. NPM1-wt 
was then associated with increased and NPM1 mutation with 
decreased proliferation for all four chemokine receptor antag-
onists: AMD3100 (CXCR4 antagonist; χ2 likelihood analyses, 
p  =  0.003), J113863 (CCR1/CCR3 antagonist, p  =  0.011), 
BX513 (CCR1 antagonist, p  =  0.012), and BX471 (CCR1 
antagonist, p  =  0.004). Thus, growth-modulating effects of 
several chemokines differed between NPM1-wt and NPM1-
mutated patients.
•	 FAB classification, CD34 expression, Flt3 mutations. The effects 
of cytokine targeting showed significant associations neither 
with differentiation nor with Flt3 mutations (data not shown).
We also did a clustering analysis of the overall results 
(Figure 7) showing that especially the effect of chemokine inhibi-
tion differed among patients; growth reduction by CCR1/CXCR4 
inhibition was seen especially for a subset of patients with normal 
cytogenetics and NPM1 mutations. Based on this analysis, our 
patients could be classified into three different groups (no or 
minor effect, decreased proliferation, increased proliferation); 
these three groups did not significantly differ with regard to 
constitutive release of supra-additive coculture levels for IL-6, 
bFGF, or chemokines. Thus, these differences among patients are 
not caused by differences in cytokine release during coculture. 
Based on our overall results, we conclude that AML patients are 
heterogeneous also with regard to the effect (i.e., responsiveness) 
of single cytokines on AML cell proliferation in the presence of 
normal bone marrow MSCs, but despite this heterogeneity the 
final/overall cytokine-mediated MSC effect is increased AML cell 
proliferation for the majority of patients.
chemokine-Mediated signaling increases 
Msc Proliferation in the Presence  
of aMl cells
We further investigated the effects on MSC24539 proliferation 
of the same antibodies and antagonists as described above 
during coculture with AML cells from the same 32 patients. 
Anti-bFGF, anti-IL-6, and the CCR1 antagonist BX513 had only 
minimal effects (data not shown). In contrast, a significant anti-
proliferative effect was seen for the CXCR4 inhibitor AMD3100 
(p <  0.0001), the CCR1/CCR3 inhibitor J113863 (p =  0.009), 
and the CCR1 antagonist BX417 (p = 0.015). Statistical analyses 
based on categorized data (i.e., increased, unaltered, decreased 
proliferation) showed associations between the CXCR4 mediated 
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antiproliferative effect and monocytic AML cell differentiation 
(p = 0.009) and favorable karyotype (p = 0.025). These observa-
tions suggest that CCR1-, CXCR4-, and possibly CCR3-mediated 
signaling is important for the regulation of MSC proliferation in 
cocultures, and these results further illustrate that this bidirec-
tional cytokine-mediated crosstalk between MSCs and AML cells 
affect not only the AML cells but also the MSCs.
DiscUssiOn
Acute myeloid leukemia is a heterogeneous and aggressive 
malignancy; the long-term AML-free survival is only 50% even 
for younger patients who receive intensive chemotherapy and the 
majority of elderly patients who only receive leukemia-stabilizing 
treatment have a median survival of less than 1 year (36). Recent 
experimental studies suggest that both adhesion of AML cells 
to osteoblasts and MSCs (31, 37) and the release of soluble fac-
tors from the latter (38) are important for chemoresistance and 
thereby the risk of leukemia relapse from residual disease (35, 37). 
Malignant myeloid cells can also alter the functional characteris-
tics of MSCs and thereby create a microenvironment that favors 
leukemic hematopoiesis (31, 39). Hence, therapeutic targeting of 
AML-supporting stromal cells may become a possible strategy 
to indirectly target the leukemia cells. In the present study, we 
therefore investigated the AML-supporting effects of bone mar-
row MSCs mediated through the local cytokine network for a 
large group of unselected leukemia patients.
Effects of stromal cells on primary human AML cells have also 
been investigated in previous studies (40–43), but none of these 
studies focused on the cytokine-mediated crosstalk between 
AML cells and MSCs. There were also several other differences: 
(i) only a low number of patients (41) or a low number of highly 
selected patients (42, 43) were examined; it is thereby difficult 
to address the question of patient heterogeneity; (ii) some of the 
studies used AML cell lines and not primary leukemic cells in 
parts of their experiments (42, 43); (iii) the previous studies used 
a stromal cell line (42, 43) or a single MSC donor (43). Thus, our 
present study extend the knowledge through its broader focus on 
the cytokine network and identification of mediators responsible 
for the leukemia-supporting effect of MSCs, studies of a large and 
unselected patient population, thereby addressing the question of 
patient heterogeneity, and the use of bone marrow MSCs derived 
from several donors.
Our viability assay has been described in detail in a previous 
publication (25). The AML cell population shows a hierarchi-
cal organization with a small number of leukemic stem cells, a 
minority of colony-forming proliferating cells and a majority of 
cells that shows spontaneous apoptosis during the first days of 
in vitro culture (25, 44). The number of viable cells will thereby 
decrease during culture and after four days of culture the viability 
will often be as low as 10–20% even for patients who show strong 
proliferative responses. This decreased viability during culture 
despite detectable proliferation shows that the viability of the total 
leukemic cell population mainly reflects the characteristics of the 
non-proliferating majority of AML cells and not the prolifera-
tion of a minor subset, i.e., survival and proliferation should be 
regarded as only partially overlapping characteristics. This is also 
supported by our recent results where a relatively small increase 
in AML cell viability during coculture was not exclusively seen 
for patients with undetectable proliferation but also for several 
other patients, and even patients with undetectable proliferation 
showed significantly increased viability (and several of them 
showed a relatively strong increase) after coculture with MSCs.
We used an experimental model based on transwell cocultures 
where MSCs and AML cells were separated by a semipermeable 
membrane; effects mediated through the bidirectional cytokine-
mediated crosstalk could thereby be studied without any influ-
ence of additional effects mediated through direct cell contact. 
We used a culture medium supplemented by inactivated FBS and 
l-glutamine that is suitable for culture of both MSCs and primary 
AML cells (16). The MSCs then mediated antiapoptotic effects 
for all but three of the 51 AML patients included in the study. 
Furthermore, a large majority of patients (40 out of 51) showed 
growth enhancement in the presence of bone marrow MSCs, and 
this enhancement was seen both for short- and long-term AML 
cell proliferation, and for three different healthy MSC donors 
tested in independent experiments. The last 11 patients did not 
show detectable AML cell proliferation either in medium alone 
or during coculture with MSCs.
Primary AML cells show spontaneous or stress-induced 
apoptosis during in vitro culture, and our results demonstrated 
that MSCs can reduce this apoptosis. Our present results demon-
strate that this antiapoptotic effect is also seen in the presence of 
cytarabine, i.e., the MSCs can also rescue primary AML cells from 
the combined effect of spontaneous and drug-induced apoptosis. 
However, we tested a cytarabine concentration that corresponds 
to systemic (i.e., serum) cytarabine levels reached during in vivo 
chemotherapy (50  nM), and in addition, a concentration cor-
responding to the steady-state levels during conventional cytara-
bine treatment with 100–200 mg/m2. A reduction of cell viability 
corresponding to more than 5% was seen only for approximately 
half of the patients when testing 50 nM cytarabine in the initial 
dose-response experiments in transwell cocultures, and in 
direct-contact cocultures. Both our experiments with  transwell 
cocultures and cytarabine but especially the direct-contact 
experiments with 500  nM cytarabine showed that MSCs can 
counteract the proapoptotic effect of cytarabine, and at least for 
certain patients the cytokine-mediated crosstalk contributes to 
this effect. However, further studies are required to characterize 
and explain this patient heterogeneity and to clarify whether this 
variation is seen also for other chemotherapeutic agents.
The local cytokine network was also altered during AML-MSC 
coculture; the levels of three mediators were relatively low (Tie-2, 
HGF, and VEGF), whereas especially CXCL1/5, IL-1β/10, TNFα, 
MMP-1, G-CSF, and GM-CSF showed supra-additive effects 
in cocultures. A strong supra-additive effect for a subset of the 
mediators was especially seen for a patient subset also character-
ized by monocytic differentiation, high cell viability in coculture, 
and strong AML cell proliferation both when cultured in medium 
alone and in the cocultures with MSCs. The constitutive mediator 
release by AML cells cultured alone also differed considerably 
among patients, and despite the supra-additive effect for several 
cytokines, there was still a significant correlation for all but one 
mediator between the levels for AML cells cultured alone and 
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in cocultures. Thus, individual differences between patients with 
regard to constitutive cytokine release by the AML cells are also 
maintained during coculture with MSCs.
We characterized the cytokine network in MSC/AML cell 
transwell cocultures in a previous study that also included a char-
acterization of the effect of the AML-MSC crosstalk on the MSCs 
(16). The study included a smaller number of patients, but the 
effects of AML cells on the MSC showed only a limited variation 
among patients. Both MSCs and AML cells showed to contribute 
to the altered cytokine network during coculture, and the relative 
importance of MSCs and leukemic cells differed among cytokines. 
First, both primary human AML cells and bone marrow MSCs 
showed constitutive release of several cytokines, but the leukemic 
cells often showed a broader constitutive release profile than the 
MSCs (16). Second, the constitutive release by normal MSCs 
shows relatively small variations among individuals (16), whereas 
the constitutive leukemia cell release profile differed consider-
ably among patients (16, 45). Third, cocultured MSCs showed 
increased mRNA expression of several cytokines, especially 
CCL and CXCL chemokines, as well as increased expression of 
several mediators of the cytokine-inducing NFκB pathway (16); 
signaling through this pathway induces increased constitutive 
release of several cytokines (45). Finally, there is a wide variation 
among patients in the constitutive release of several cytokines by 
their AML cells, and this variation is often maintained also in 
the presence of MSCs. Thus, the cytokine levels in our cocultures 
are probably determined by an NFκB-induced increase in the 
constitutive release by the MSCs and by maintenance of differ-
ences among patients in the constitutive release by the AML cells.
We investigated possible molecular mechanisms behind the 
growth-enhancing and antiapoptotic effect of MSCs on primary 
human AML cells. These experiments included leukemic cells 
from 10 patients. The PI3K–Akt–mTOR pathway is often consti-
tutively activated in AML cells and is important for cell survival, 
proliferation and metabolism (46, 47). We therefore compared the 
activation/phosphorylation of Akt, mTOR, and mediators down-
stream to mTOR (S6K1, 4E-BP1) after incubation with medium 
alone or 50% MSC-conditioned medium. Akt phosphorylation 
did not differ among patients, whereas increased phosphoryla-
tion was detected for mTOR and its downstream mediators.
We also compared the effect of MSC-conditioned medium on 
the phosphorylation of the H2AX histone that is phosphorylated 
by the ATM kinase as part of the DNA damage response. There 
will be a background or constitutive level of H2AX phospho-
rylation, and this level seems to reflect a DNA damage response 
initiated by endogenous formation of reactive oxidant species as a 
byproduct from oxidative phosphorylation (48). However, DNA 
damage response with increased H2AX phosphorylation can also 
be an early event during apoptosis (29). Primary human AML 
cells seem to have a suppressed DNA damage response due to 
increased expression of double-stranded RNA-activated protein 
kinase, and high expression of this kinase in the AML cells is 
thereby associated with an inhibited DNA damage response 
reflected as a low percentage of H2AX phosphorylation (49, 50). 
H2AX phosphorylation can also be seen without DNA damage 
(51). In our experiments we observed a significant increase in 
H2AX phosphorylation after culture with MSC-conditioned 
medium (Wilcoxon’s test; p = 0.005). However, this increase of 
H2AX phosphorylation combined with increased cell viability 
suggests that the increased H2AX phosphorylation is not an 
effect of increased apoptosis. In our opinion, the most likely 
explanation is a reversal of the AML-associated decrease in 
the DNA damage response; this may be caused by IL-6 that is 
present at high levels in MSC-conditioned medium (see Table 2) 
and which is known to strengthen the DNA damage response 
(30). An alternative explanation could be that increased mTOR 
mediated signaling causes increased oxidative phosphorylation 
and thereby increased constitutive (i.e., oxidative) DNA damage 
(52). Thus, both increased mTOR activation and increased DNA 
damage responsiveness can contribute to the effects of MSCs on 
primary human AML cells.
Finally, cytokine neutralization and receptor blocking showed 
that AML cells derived from different patients were heterogene-
ous with regard to the effects of various cytokines on AML cell 
viability/proliferation. One of the cytokines with differential 
effects was CXCL12, which is highly released by MSCs. Even 
though cells with Flt3-ITD have shown increased CXCR4 
expression (13) and signaling through the CXCL12-CXCR4 axis, 
the differential effect of CXCR4 blocking showed no significant 
association with Flt3-ITD.
Several soluble mediators that were detected at relatively high 
levels in our cocultures have been linked with remodeling of the 
bone marrow stem cell niche into a leukemia-permissive niche: (i) 
angiogenic growth factors like VEGF (53, 54), bFGF, Ang-1, and 
its receptor Tie-2 (31); (ii) IL-6 (32), which also can upregulate 
VEGF levels (55); (iii) CCL3, which is thought to expand MSCs 
and drive them into a leukemia-supporting phenotype (39); (iv) 
CXCL12, which is constitutively expressed by MSCs (37), causes 
homing of leukemic cells to the bone marrow (56, 57) and func-
tions as a regulator of proliferation, cell cycle progression, and 
survival of leukemic cells (35, 58). Our previous studies could not 
detect any evidence for osteoblastic or adipocytic MSC differen-
tiation during MSC/AML cell cocultures, even though the global 
gene expression profile of normal MSCs was seen after coculture 
of MSC and AML cells in transwell cultures (16).
MSCs showed constitutive release of several mediators, and 
we used cytokine-neutralizing antibodies or receptor-blocking 
agents to identify cytokines that contributed to the antiapoptotic 
and growth-enhancing effect of MSCs on the AML cells. We then 
investigated cytokines that were released by MSCs at relatively 
high levels, showed high levels during coculture and are known 
to function as growth factors for primary human AML cells. First, 
antibodies against HGF and VEGF tested separately had no or 
only minimal effects on AML cell proliferation and were only 
examined in the initial experiments. Second, IL-6 neutralization 
inhibited AML cell proliferation for the subset of patients with 
normal cytogenetics, whereas reduced proliferation upon bFGF 
neutralization was only observed in NPM1-wt cells and this is 
consistent with previous observations of AML cells cultured 
alone (33). Third, the effects of several chemokine receptor 
blockers (including CXCL12/CXCR4 blocking) also differed 
among patients, especially when comparing patients with and 
without NPM1 mutations. Based on the overall results, we con-
clude that AML patients are heterogeneous with regard to effects 
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of individual cytokines on AML cell viability and proliferation 
during MSC/AML cells coculture. However, despite this varia-
tion, the final overall cytokine-mediated effects of the MSCs are 
increased viability and growth enhancement probably caused by a 
combined effect of several cytokines, and the cytokines contribut-
ing to this effect seem to differ among patients.
In contrast to the divergent effects of cytokine neutralization/
blocking on AML cells, these interventions had more uniform 
effects on MSC proliferation during coculture as MSC prolifera-
tion significantly decreased in response to chemokine receptor 
blocking (CCR1, CCR3, CXCR4) agents. Both AML cells and 
MSCs show constitutive release of several ligands for these recep-
tors, suggesting that autocrine or paracrine loops involving these 
receptors are important for the regulation of MSC proliferation 
(59). This hypothesis is also supported by the observation that 
CCL3 expression by malignant myeloid cells is linked with higher 
MSC growth rates (39).
Systemic plasma levels of both IL-6, bFGF, and several 
chemokines have been investigated in human AML. IL-6 levels 
are increased in patients with untreated AML and high levels 
seem to be associated with decreased survival (60). In contrast, 
the results for plasma bFGF levels are conflicting and both nor-
mal and increased plasma levels have been described for patients 
with untreated AML, but none of these studies have described 
any prognostic impact of bFGF levels (61–63). As reviewed by 
Reikvam et al. (64), several studies have investigated the systemic 
(plasma or serum) levels of various chemokines; besides normal, 
both increased and decreased levels have been described for most 
of the investigated CCL and CXCL chemokines in patients with 
untreated AML. Even though only a small minority of patients 
(<15%) shows detectable CXCL12 release during in vitro culture 
and most of these patients show only low release (45), increased 
serum CXCL12 levels have been described in patients with 
untreated AML, including increased levels of the cleaved active 
form. These observations may suggest that constitutive AML cell 
release of these cytokines has clinical relevance in human AML. 
However, the observations should be interpreted with great care 
because these cytokines can be released by several normal cells 
and not only AML cells, some of these cytokines may be a part 
of the acute phase reaction, and the systemic levels reflect the 
binding between release and binding/degradation, Thus, altered 
systemic levels may not reflect AML cell release or the local levels 
in the bone marrow microenvironment.
cOnclUsiOn
Our present study shows that even though AML is a heterogene-
ous disease and the response of primary AML cells to the various 
MSC-derived cytokines during MSC-AML cell coculture differs 
among patients, the final effect of MSC-derived cytokines on 
primary AML cells is increased proliferation and viability. Our 
overall results suggest that therapeutic targeting of the cytokine-
mediated AML-supporting effects probably as MSC-directed 
strategies which inhibit the release of several cytokines, or 
alternatively receptor blocking could be tried in selected patients.
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